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ABSTRACT
The Absorption, Distribution, Metabolism, Elimina-
tion, and Toxicity (ADMET) properties of drug candi-
dates are estimated to account for up to 50% of all clinical
trial failures1,2. Predicting ADMET properties has there-
fore been of great interest to the cheminformatics and
medicinal chemistry communities in recent decades. Tra-
ditional cheminformatics approaches, whether the learner
is a random forest or a deep neural network, leverage
fixed fingerprint feature representations of molecules. In
contrast, in this paper, we learn the features most rele-
vant to each chemical task at hand by representing each
molecule explicitly as a graph, where each node is an
atom and each edge is a bond. By applying graph con-
volutions to this explicit molecular representation, we
achieve, to our knowledge, unprecedented accuracy in
prediction of ADMET properties. By challenging our
methodology with rigorous cross-validation procedures
and prospective analyses, we show that deep featurization
better enables molecular predictors to not only interpolate
but also extrapolate to new regions of chemical space.
I. INTRODUCTION
Only about 12% of drug candidates entering human
clinical trials ultimately reach FDA approval2. This low
success rate stems to a significant degree from issues
related to the absorption, distribution, metabolism, elimi-
nation, and toxicity (ADMET) properties of a molecule.
In turn, ADMET properties are estimated to account for
up to 50% of all clinical trial failures1,2.
Over the past few years, Mercki has been heavily in-
vested in leveraging institutional knowledge in an effort
to drive hypothesis-driven, model-guided experimenta-
tion early in discovery. To that end, in silico models
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have been established for many of our early screening
assay endpoints deemed critical in the design of suitable
potential candidates in order to selectively invest avail-
able resources in chemical matter having the best possible
chance of delivering an efficacious and safe drug candidate
in a timely fashion3,4.
Supervised machine learning (ML) is an umbrella term
for a family of functional forms and optimization schemes
for mapping input features representing input samples to
ground truth output labels. The traditional paradigm of
ML involves representing training samples as flat vectors
of features5. This featurization step frequently entails
domain-specific knowledge. For instance, recent work in
protein-ligand binding affinity prediction represents, or
featurizes, a protein-ligand co-crystal complex with a flat
vector containing properties including number of hydrogen
bonds, number of salt bridges, number of ligand rotatable
bonds, and floating point measures of such properties as
hydrophobic interactions6–8.
In the domain of ligand-based QSAR, cheminformati-
cians have devised a variety of schemes to represent
individual molecules as flat vectors of mechanized fea-
tures. Circular fingerprints9 of bond diameter 2, 4, and 6
(ECFP2, ECFP4, ECFP6, respectively) hash local neigh-
borhoods of each atom to bits in a fixed vector. In con-
trast, atom pair features10 denote pairs of atoms in a given
molecule, the atom types, and the minimum bond path
length that separates the two atoms. In a supervised ML
setting, regardless of specific featurization, all such fixed
length vector featurizations will be paired with a learning
algorithm of choice (e.g., Random Forests, Support Vector
Machines5, multilayer perceptron deep neural networks,
i.e. MLP DNN’s11) that will then return a mapping of
features to some output assay label of interest.
While circular fingerprints, atom pair features, MACCS
keys12, and related generic schemes have the potential to
supersede the signal present in hand-crafted features, they
are still inherently limited by the insuperable inefficiency
of projecting a complex multidimensional object onto a
single dimension. Whereas graph convolutions win with
molecules by exploiting the concept of bond adjacency,
two-dimensional convolutions win with images by exploit-
ing pixel adjacency, and recurrent neural networks win
by exploiting temporal adjacency, there is no meaning to
proximity of bits along either an ECFP or pair descrip-
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2tor set of molecular features. For instance, considering
the pair descriptor framework, an sp3 carbon that is five
bonds away from an sp2 nitrogen might denote the first
bit in the feature vector, an sp2 oxygen that is two bonds
away from an sp3 nitrogen might denote the very next
bit in the same feature vector, and an sp3 carbon that
is four bonds away from an sp2 nitrogen might denote
the hundredth bit in the feature vector. Put in descriptor
language, a feature like “CX3sp3-04-NX1sp2” is conceptu-
ally similar to “CX20sp3-04-NX2sp2”, but the descriptors
are treated as fully unrelated in descriptor-based QSAR
while graph convolutional approaches could separate the
“element” component from the “hybridization” component
and both from the “bond distance” component. The
conceptual proximity between qualitatively similar de-
scriptors is weakened by the arbitrary arrangement of
bits in the featurization process and therefore must be
“re-learned” by the supervised machine learning algorithm
of choice.
To both compare and contrast chemical ML on fixed
vector descriptors with chemical deep learning on graph
features, we write out a multilayer perceptron (MLP) and
a graph convolutional neural network (GCNN) side-by-
side (Figure 1). In Figure 1, each molecule is represented
either by a flat vector x for the MLP or by both an
Natoms×Natoms adjacency matrix A and an Natoms×fin
per-atom feature matrix X for the GCNN. The GCNN
begins with K graph convolutional layers. It then pro-
ceeds to a graph gather operation that sums over the
per-atom features in the last graph convolutional hidden
layer: x(NN) =
∑
atomsH
(K), where the differentiable
x(NN), by analogy to the fixed input x of the MLP, is a
flat vector graph convolutional fingerprint for the entire
molecule, and H
(K)
i is the feature map at the K
′th graph
convolutional layer for atom i. The final layers of the
GCNN are identical in form to the hidden layers of the
MLP. The difference, therefore, between the MLP and the
GCNN lies in the fact that x for MLP is a fixed vector of
molecular fingerprints, whereas x(NN) of the GCNN is an
end-to-end differentiable fingerprint vector: the features
are learned in the graph convolution layers.
Another noteworthy parallel arises between the MLP
hidden layers and the GCNN graph convolutional layers.
Whereas the first MLP layer maps h(1) = ReLU(W (1) ·x),
the GCNN inserts the adjacency matrix A between W and
atom feature matrix X: H(1) = ReLU(W (1) ·A ·X). Note
that, while the feature maps X,H(1), ...,H(K) change
at each layer of a GCNN, the adjacency matrix A is
a constant to be re-used at each layer. Therefore, in
a recursive manner, a given atom is passed information
about other atoms succesively further in bond path length
at each graph convolutional layer.
Since the advent of the basic graph convolutional neural
network, a spate of new approaches13–17 have improved
upon the elementary graph convolutional layers expressed
in Figure 1. Here, we train neural networks based on the
PotentialNet17 family of graph convolutions.
h
(1)
i = GRU
xi, Net∑
e
∑
j∈N(e)(vi)
NN (e)(xj)

...
h
(K)
i = GRU
h(bK−1)i , Net∑
e
∑
j∈N(e)(vi)
NN (e)(h
(bK−1)
j )

h(NN) = σ
(
i(h(K), x)
)

(
j(h(K))
)
h(FC0) =
NLig∑
j=1
h
(NN)
j
h(FC1) = ReLU
(
W (FC1)h(FC0)
)
...
h(FCK) = W (FCK)h(FCK−1)
(1)
where h
(k)
i represents the feature map for atomi at graph
convolutional layer k; i, j, and NN are neural networks,
NLig is the number of ligand atoms, {W} are weight ma-
trices for different layers. The GRU is a Gated Recurrent
Unit which affords a more efficient passing of information
to an atom from its neighbors. In this way, whereas one
might view the standard GCNN displayed in Figure 1
as more analogous to learnable and more efficient ECFP
featurization, one might view the PotentialNet layers in
Equation 1 as being more analogous to a learnable and
more efficient pair descriptor10 featurization.
In this paper, we conduct a direct comparison of the
current state-of-the-art algorithm similar to those used by
many major pharmaceutical companies – random forests
based on atom pair descriptors – with PotentialNet (Equa-
tion 1). We trained ML models on thirty-one chemical
datasets describing results of various ADMET assays –
ranging from physicochemical properties to animal-based
PK properties – and compared results of random forests
with those of PotentialNet on held out test sets chosen by
two different cross-validation strategies (further details
on PotentialNet training are included in Methods). In ad-
dition, we ascertain the capacity of our trained models to
generalize to assays conducted outside of our institution
by downloading datasets from the scholarly literature and
conducting further performance comparisons. Finally, we
conduct a prospective comparison of prediction accuracy
of Random Forests and PotentialNet on assay data of new
chemical entities recorded well after all model parameters
were frozen in place.
II. RESULTS
The primary purpose of supervised machine learning is
to train computer models to make accurate predictions
3FIG. 1: Comparison of algorithms for multilayer perceptron versus graph convolution.
Multi-Layer Perceptron / 
Fully Connected Neural Network
Graph Convolutional 
Neural Network (GCNN)
h(1) = ReLU
⇣
W (1) · x
⌘
h(2) = ReLU
⇣
W (2) · h(1)
⌘
...
h(K) = ReLU
⇣
W (K) · h(K 1)
⌘
H(1) = ReLU
⇣
W (1) ·A ·X
⌘
H(2) = ReLU
⇣
W (2) ·A ·H(1)
⌘
...
H(K) = ReLU
⇣
W (K) ·A ·H(K 1)
⌘
x(NN) =
X
atoms
H(K)
h(1) = ReLU
⇣
W (1) · x(NN)
⌘
h(2) = ReLU
⇣
W (2) · h(1)
⌘
...
h(K) = ReLU
⇣
W (K) · h(K 1)
⌘
about samples that have not been seen before in the
learning process. In the discipline of computer vision,
the ability to interpolate between training samples is of-
ten sufficient for real-world applications. Such is not the
case in the field of medicinal chemistry. When a chemist
is tasked with generating new molecular entities to se-
lectively modulate a given biological target, they must
invent chemical matter that is fundamentally different
than previously known materials. This need stems from
both scientific and practical concerns; every biological tar-
get is different and likely requires heretofore nonexistent
chemical matter, and the patent system demands that,
to garner protection, new chemical entities must be not
only useful but also novel and sufficiently different from
currently existing molecules.
Cross-validation is a subtle yet critical component of
any ML initiative. In the absence of the ability to gather
prospective data, it is standard practice in ML to divide
one’s retrospectively available training data into three
disjoint subsets: train, valid, and test (though it is only
strictly necessary that the test set be disjoint from the
others). It is well known that cross-validation strategies
typically used in the vision or natural language domains,
like random splitting, significantly over-estimate the gen-
eralization and extrapolation ability of machine learning
methods18. As a result, we deploy two train-test splits
that, compared to random splitting, are at once more chal-
lenging and also more accurately reflect the real world task
of drug discovery. First, we split all datasets temporally,
training on molecules assayed before the earliest datei, se-
lecting models based on performance on molecules assayed
between datei and intermediate datej , and evaluating the
final model on held-out molecules assayed after the latest
datej . Such temporal splitting is meant to parallel the
types of progressions that typically occur in lead opti-
mization programs as well as reflect broader changes in
the medicinal chemistry field.
In addition to temporal splitting, we introduce an ad-
ditional cross-validation strategy in which we both divide
train, valid, and test sets temporally and add the following
challenge: (1) removal of molecules with molecular weight
greater than 500 gmol from the training and validation sets
and (2) inclusion of only molecules with molecular weight
greater than or equal to 600 gmol from the test set. We
denote this as temporal plus molecular weight split (Figure
2).
A. Temporal Split
In aggregate, PotentialNet achieves a 64% average
improvement and a 52% median improvement in R2
4FIG. 2: Temporal plus Molecular Weight Split. In this rigorous cross-validation procedure, one trains and selects
models based on older, smaller molecules, with the resultant best model (according to the validation set score) being
evaluated a single time on a held out test set on newer, larger molecules. Specifically, the train and validation sets are
comprised only of molecules below a certain molecular weight threshold and synthesized before a certain date, whereas
the test set is comprised only of molecules above a certain molecular weight threshold and synthesized after a certain
date.
over Random Forests across all thirty-one reported
datasets (Figure 3, Table I, Table VI). The mean R2
over the various test datasets is 0.30 for Random Forests
and 0.44 for PotentialNet, corresponding to a mean
∆R2 (PotentialNet−RandomForest) = 0.15. Among
the assays for which PotentialNet offers the most im-
provement (Figure 8) are plasma protein binding (frac-
tion unbound for both human, ∆R2 = 0.34 and rat,
∆R2 = 0.38), microsomal clearance (human: ∆R2 = 0.21,
dog: ∆R2 = 0.26, rat: ∆R2 = 0.22), CYP3A4 Inhi-
bition (∆R2 = 0.22), logD (∆R2 = 0.18), and passive
membrane absorption (∆R2 = 0.18). Meanwhile, assays
HPLC EPSA and rat clearance, which account for two
of the thirty-one assays, show no statistically significant
difference. All R2 values are reported with confidence
intervals computed according to ref19.
In addition to improvements in R2, for both cross-
validation schemes discussed, we note that the slope of
the linear regression line between predicted and experi-
mental data is, on average, closer to unity for PotentialNet
than it is for Random Forests. This difference is quali-
tatively notable in Figure 8. A corollary, which is also
illustrated by Figures 8, 9, and 10, is that PotentialNet
DNN’s perform noticeably better than Random Forest in
predicting the correct range of values for a given predic-
tion task. At our institution, this deficiency of RF is in
part rectified by ex post facto prediction rescaling, which
in part recovers the slope but makes no difference in R2.
The commercially available molecules for which Poten-
tialNet achieved the greatest improvement in prediction
versus Random Forests are displayed in Table IV. An
example of a molecule on which Random Forest renders
a more accurate prediction is shown in Table V.
B. Temporal plus Molecular Weight Split
We then investigated the cross-validation setting where
data was both (a) split temporally and (b) molecules with
MW > 500 gmol were removed from the training set while
only molecules with MW > 600 gmol were retained in the
test set (Figure 2). In aggregate, PotentialNet achieves a
153% median improvement in R2 over Random Forests
across all twenty-nine reported datasetsii (Table II, Figure
4). The mean R2 over the various test datasets is 0.12 for
Random Forests and 0.28 for PotentialNet, corresponding
to a mean ∆R2 (PotentialNet−RandomForest) = 0.16.
ii Note that PAMPA and EPSA are not included due to insufficient
number of compounds meeting the training and testing criteria.
5FIG. 3: Temporal Split: Performance of PotentialNet versus Random Forest for All Assays
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The assays for which PotentialNet offers the most im-
provement (Figure 9) are plasma protein binding (frac-
tion unbound for both human, ∆R2 = 0.38 and rat,
∆R2 = 0.47), microsomal clearance (human: ∆R2 = 0.29,
dog: ∆R2 = 0.19, rat: ∆R2 = 0.37), CYP2C8 Inhibition
(∆R2 = 0.25), logD (∆R2 = 0.25), and passive membrane
absorption (∆R2 = 0.28). Meanwhile, human hepatocyte
clearance, CYP2D6 Inhibition, rat and dog clearance, dog
halflife, human PGP (efflux), rat MRT, and rat volume
of distribution exhibit no statistically significant differ-
ence in model predictivity ( 829 of all datasets), with only
rat hepatocyte clearance being predicted less well for Po-
tentialNet as compared to Random Forests. It should
be noted that the quantity of molecules in the test sets
are smaller in temporal plus MW split as compared to
temporal only split, and therefore, it is accordingly more
difficult to reach statistically significant differences in R2
(S.I. Table IV).
The commercially available molecules for which Poten-
tialNet achieved the greatest improvement in prediction
versus Random Forests are displayed in Table IX. It is
intriguing that the same molecule undergoes the greatest
improvement for both Human Fraction Unbound as well
as CYP2D6 Inhibition.
As previous works have noted20, multitask style training
(cf. Methods) can boost – or, less charitably, inflate – the
performance of neural networks by sharing information
between the training molecules of one task and the test
molecules of another task, especially if the activities are in
some way correlated. Another advantage of the Temporal
plus Molecular Weight cross-validation approach is that
it mitigates hemorrhaging of information between assay
datasets. By introducing a minimum 100 gmol molecular
weight gap between train and test molecules, it is not only
impossible for train molecules in one task to appear as
test molecules for another task, but it also circumscribes
the similarity of any given task’s training set to any given
other task’s test set. We further investigate the relative
effect of multitask versus single task training in Supple-
mentary Table II. However, even in cases where there
is similarity or even identity between training molecules
of one assay and test molecules of another assay, in the
practice of chemical machine learning, this may in fact be
desirable in cases. For instance, if less expensive, cell-free
assays, like solubility, have a strong correlation with a
more expensive endpoint, like dog mean residence time,
6FIG. 4: Temporal plus Molecular Weight Split: Performance of PotentialNet versus Random Forest for All Assays
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it would be an attractive property of multitask learning
if solubility data on molecules in a preexisting database
could inform more accurate predictions of the animal
mean residence time of untested, similar molecules.
C. Held out data from literature
To further ascertain the generalization capacity of our
models, we obtained data from scholarly literature. In
particular, we obtained data on macrocyclic compounds
for passive membrane permeability and logD from ref21.
We observed a statistically significant increase in perfor-
mance (Table X) for both passive membrane permeabil-
ity (∆R2 (PotentialNet−RandomForest) = 0.23) and
logD (∆R2 (PotentialNet−RandomForest) = 0.21).
The four molecules for which PotentialNet exhibits the
greatest improvement in predictive accuracy over Random
Forests are shown in Table XI.
The second molecule in Table XI is experimentally
quite permeable, which PotentialNet correctly identifies
but Random Forests severely underestimates. Note that
the aliphatic tertiary amine would likely be protonated
and therefore charged at physiologic pH. The proximity of
an ether oxygen may “protect” the charge, increasing the
ability to passively diffuse through lipid bilayers. Because
of the relative efficiency with which information traverses
bonds in a graph convolution as opposed to the fixed
pair features that are provided to the random forest, it is
intuitively straightforward for a graph neural network to
learn the “atom type” of a high pKa nitrogen in spatial
proximity to an electron rich oxygen, whereas pair features
would rigidly specify an aliphatic nitrogen three bonds
away from an aliphatic oxygen.
D. Feature Interpretation
Feature interpretation remains a fledgling discipline in
many areas of deep learning. We posit a simple method
here to probe a given graph convolutional neural net-
work to expose intuitive reasons driving that network’s
decision-making process. Recall that the basic graph con-
volutional update is h(1) = ReLU
(
W (1) ·A ·X). For a
given molecule xˆ with predicted property yˆ, we can use
the backpropagation algorithm to determine the gradient,
7or partial derivative per feature, on the input. We define
the feature-wise importance Imp(atomi) of atomi as:
Imp(atomi) =
(fin)∑
j=0
∂NN(A,X)
∂Xij
(2)
where fin is the initial number of features per atom
(number of columns of X) and Xij is the j
′th feature of
atomi.
By a related metric, we can posit the substructure, or
functional group, of size S atoms of a molecule that has
the greatest impact on the graph convolutional neural
network’s prediction by:
argmaxsubgraph G’
∑
atomj∈G′
Imp(atomj) (3)
The above comprises a plausible route for feature inter-
pretation in graph convolutional neural networks. While
a rigorous evaluation of this approach will remain the sub-
ject of future work, we illustrate how it would function
with a large molecule example. Let us reexamine the case
of the molecule in Table XI that is correctly identified by
PotentialNet as membrane permeable (and misidentified
by Random Forests as impermeable). Intriguingly, the
feature importance score (Equation 2) points to the two
carbons neighboring the tertiary amine nitrogen, and the
amide carbon and nitrogen as the four most important
atoms for determining permeability (Figure 11a, Equa-
tion 2). The importance of the tertiary amine adjacent
atoms certainly correlates with chemical intuition. Mean-
while, the amide group is seen as important by both
individual per-atom gradient ranking as well as by maxi-
mal substructure importance (Figure 11b, Equation 3).
The interpretation of the amide’s high importance is less
obvious, though several studies22,23 have examined the
influence of macrocycle amides and permeability. For
instance, it has been proposed22 that amide groups in
the main ring of macrocycles stabilize conformations that
enable intramolecular hydrogen bond formation, thereby
reducing the effective polar surface area of the molecule.
It is possible that the graph neural network is learning
a correlation between macrocyclic amides and reduced
polar surface area.
E. Prospective Study
1. Overall Prospective Performance on Nov, 2018 - Feb,
2019 Data
In September, 2018, we froze the parameters of Random
Forest and PotentialNet models trained on all available
assay data recorded internally at Merck up to the end
of August, 2018. After approximately two months had
elapsed after the registration of the last training data
point, we evaluated the performance of those a priori
frozen models on new experimental assay data gathered
on compounds registered between November, 2018 and
the end of February, 2019. Not only does this constitute
a prospective analysis, but a particularly rigorous one in
which there is a two month gap between training data
collection and prospective model evaluation, further chal-
lenging the generalization capacity of the trained models.
For statistical power, we chose to evaluate performance
on all assays for which at least ten compounds were ex-
perimentally tested the period Nov, 2018 - Feb, 2019.
Over these twenty-seven assays, Random Forest achieved
a median R2 of 0.32, whereas PotentialNet achieved a
median R2 of 0.43 for a median ∆R2 = 0.10 (Table III).
Performance of each assay can be found in Figure 5 and
Table VIII, and scatter plots of predicted versus experi-
mental values for several assays can be found in Figure
10. While it makes no difference in R2, we have chosen to
scale the values predicted by both Random Forests and by
PotentialNet to match the mean and standard deviation
of the distribution of assay data in the training set to
more faithfully reflect how these models would be used
practically in an active pharmaceutical project setting.
2. Performance on Two Specific Projects
To assess performance on individual projects, we ap-
plied the August, 2018, models to prediction of rat plasma
fraction unbound on two currently active lead optimiza-
tion projects at Merck. The results (Figure 6) suggest
that the performance on the individual projects are simi-
lar to the temporal split and temporal + molecular weight
split results.
III. DISCUSSION
Preclinical drug discovery is a critica, and often rate-
limiting stage of the broader pharmaceutical development
pipeline. While estimates vary between studies, recent
analyses estimate the capitalized cost of preclinical dis-
covery per FDA-approved drug as anywhere between $89
Million and $834 Million24–26. The multi-objective opti-
mization among potency and ADMET properties, which
can entail vexing trade-offs, is a critical bottleneck in
preclinical discovery27,28. More accurate prediction of
ADMET endpoints can both prevent exploration of un-
desirable chemical space as well as facilitate access to
desirable regions of chemical space, thereby making pre-
clinical discovery not only more efficient but perhaps more
productive as well.
To assess if a modern graph convolutional neural
network17 succeeds in more accurately predicting AD-
MET endpoints, we conducted a rigorous performance
comparison between GCNN and the previous state-of-
the-art random forest based on cheminformatic features.
With an emphasis on rigor, we included a total of thirty-
8FIG. 5: Prospective Study. All model parameters for both PotentialNet and Random Forests were frozen in August,
2018. Subsequently, performance of both models was compared for new assay data collected on compounds registered
from Nov, 2018 - Feb, 2019.
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one assay datasets in our analysis, employed two cross-
validation splits (temporal split18 and a combined temporal
plus molecular weight split), and made predictions on a
publicly available held-out test set. Finally, we made
prospective predictions with both random forests and
with PotentialNet and then compared with experimental
results.
Encouragingly, statistical improvements were observed
in each of the four aforementioned validation settings.
In the temporal split setting, across thirty-one tasks,
Random Forests achieved a mean R2 of 0.30, whereas
PotentialNet achieved a mean R2 of 0.44 (Table I). In the
temporal plus molecular weight split setting – where only
older smaller molecules were included in the training set
while only newer larger molecules included in the test set
– across twenty-nine tasks, Random Forests achieved a
mean R2 of 0.12, whereas PotentialNet achieved a mean
R2 of 0.28 (Table II). In the final pseudo-prospective
validation setting, we assessed the ability of pre-trained
Random Forests and pre-trained PotentialNet models
to predict passive membrane permeability and logD on
an experimental dataset on macrocycles obtained from
the literature21. In this setting, for passive membrane
permeability, Random Forests achieved an R2 of 0.15
whereas PotentialNet achieved an R2 of 0.38; for logD,
Random Forests achieved an R2 of 0.39 whereas Poten-
tialNet achieved an R2 of 0.60 (Table IX).
While the three described retrospective investigations
are more rigorous than random splitting and are meant
to more faithfully reflect the generalization capacity of
a model in the practical real world of pharmaceutical
chemistry, we also believe that prospective validation is
important whenever the resources are available to do so.
To this end, we made predictions on twenty-three assays,
each of which contained measurements for new chemical
entities synthesized and evaluated after November, 2018
(the last data point for model training was collected in
August, 2018). In aggregate, there is a mean ∆R2 of 0.10
of PotentialNet over Random Forests. This improvement
in accuracy in a future and relatively constrained time
window is largely consistent with that prognosticated by
the retrospective temporal split study and is encouraging
9FIG. 6: Prospective prediction of rat fraction unbound in plasma (rat fu,p) in two active projects using random forest
models (top row) and potential net models (bottom row), for compounds experimentally tested between September
and December 2018. Data for Project 1 and Project 2 is for 97 and 123 compounds, respectively.
Project 1
lo
g 
(R
F 
ra
t f
u
pl
as
m
a)
log (Rat fu plasma)
lo
g 
(P
N
et
ra
t f
u
pl
as
m
a)
log (Rat fu plasma)
lo
g 
(R
F 
ra
t f
u
pl
as
m
a)
log (Rat fu plasma) log (Rat fu plasma)
lo
g 
(P
N
et
ra
t f
u
pl
as
m
a)
Project 1
Project 2
Project 2
for the utility of deep featurization in a predictive capacity
for drug discovery.
Historically, as a discipline, machine learning arose from
statistical learning, and a key line of inquiry in statis-
tics involves extricating potentially confounding variables.
Compared with random forests, we introduce several al-
gorithmic changes at once: use of neural network instead
of random forest; use of graph convolution as a neural
network architecture based on a graph adjacency and
feature matrices as input rather than either RF or MLP
based on flat 1D features; and use of a variant of multi-
task learning rather than single task learning. How much
of the performance gain accrued by PotentialNet can be
attributed to each of the aforementioned changes? To
investigate, we conducted an algorithm ablation study
to compare performance contributions (Supplementary
Tables II and VI; we also include xgboost for additional
comparison). It is reasonable to contend that one should
solely compare random forest with single task neural net-
works since the former is incapable of jointly learning on
several assay datasets simultaneously. However, one of the
intuitive advantages of a GCNN over either RF or MLP
is that a GCNN can learn the atomic interaction features
relevant to the prediction task at hand. Therefore, we
aver that the most reflective comparison is to apply best
practices that are accessible by each technique. Not only
can graph convolutions learn the features, but adding
different molecules from different tasks allows networks
to learn more accurately both through the effect of task
correlation and learning richer features by incorporating
a greater area of chemical space.
While we are restricted with respect to the compounds
in our training data that we can disclose, we can share
select publicly disclosed compounds that happened to
have been tested in the assays discussed in this work. Ta-
ble IV lists commercially available compounds for which
PotentialNet’s predictions are most improved compared
to Random Forests’ predictions in the temporal split set-
ting. For example, the first compound, Methyl 4-chloro-2-
iodobenzoate, has an experimental logD of 3.88, Random
10
Forests predicts logD to be 2.26, and PotentialNet pre-
dicts logD to be 3.70. Neural network interpretation
remains a discipline in its infancy and therefore renders it
challenging to pinpoint exactly which aspect of either the
initial featurization or the network enables PotentialNet
to properly estimate the logD while Random Forests signif-
icantly underestimates it. As a hypothetical analysis, pair
features would include such terms as “carbonyl oxygen
that is three bonds away from ether carbon,” “carbonyl
oxygen that is four bonds away from aromatic iodine,”
and “carbonyl oxygen that is six bonds away from an
aromatic chlorine.” There is no sense that it is the same
carbonyl carbon that has all of these properties. In stark
contrast, by recursively propagating information, a graph
convolution would confer a single, dense “atom type” on
the carbonyl oxygen that would reflect its identity as a
halogenated benzaldehyde oxygen.
More accurate prediction of ADMET endpoints can
be a torch29light guiding creative medicinal chemists as
they explore uncharted chemical space en route to the
optimal molecule. The results delineated in this paper
demonstrate that deep-feature learning with graph con-
volutions can systematically and often quite significantly
outperform random forests based on fixed fingerprints.
We therefore deem it advisable for pharmaceutical sci-
entists to consider integrating deep learning in general
and graph convolutions in particular in their modeling
pipelines.
METHODS
PotentialNet (Equation 1)17 neural networks were con-
structed and trained with PyTorch29. Multilayer per-
ceptron (MLP) neural networks were trained with the
assistance of the MIX library that is internal to Merck
(more details below). Following previous works30, we
make extensive use of multitask learning to train our Po-
tentialNet models. We modified the standard multitask
framework to save different models for each task on the
epoch at which performance was best for that specific task
on the validation set (Figure 7). In that way, we employ an
approach that draws on elements of both single and mul-
titask learning. Custom Python code was used based on
RDKit31 and OEChem32 with frequent use of NumPy33
and SciPy34. Networks were trained on chemical element,
formal charge, hybridization, aromaticity, and the total
numbers of bonds, hydrogens (total and implicit), and
radical electrons. Random forest were implemented using
both scikit-learn35 and MIX; all sklearn-trained random
forests models were trained with 500 trees and
√
nfeatures
per tree; xgboost models were trained using MIX.
QSAR Descriptors: Chemical descriptors, termed
“APDP” used in this study for random forests, xgboost,
and MLP DNN’s are listed as follows. All descriptors
are used in frequency form, i.e. we use the number of
occurrences in a molecule and not just the binary presence
or absence. APDP denotes the union of AP, the origi-
nal “atom pair” descriptor from ref10, and DP descriptors
(“Donor acceptor Pair”), called “BP” in ref.36. Such
APDP descriptors are used in most of Merck’s QSAR
studies and in Merck’s production QSAR. Both descrip-
tors are of the form: “Atom typei – (distance in bonds) –
Atom typej”
For AP, atom type includes the element, number of
nonhydrogen neighbors, and number of pi electrons; it is
very specific. For DP, atom type is one of seven (cation,
anion, neutral donor, neutral acceptor, polar, hydrophobe,
and other); it contains a more generic description of
chemistry.
QSAR methods: All methods are used in regression
mode, i.e. both input activities and predictions are
floating-point numbers. All appropriate descriptors are
used in the models, i.e. no feature selection is done. When
random forests are not trained with scikit-learn, they are
trained with the Merck MIX library that in turn calls the
R module RandomForest37, which encodes the original
method of ref.38 and first applied to QSAR in ref.39. The
default settings are 100 trees, nodesize=5, mtry=M/3
where M is the number of unique descriptors.
MLP Deep neural networks (DNN): We use Python-
based code obtained from the Kaggle contest and de-
scribed in ref40. We use parameters slightly different
than the “standard set” described in that paper: Two
intermediate layers of 1000 and 500 neurons with 25%
dropout rate and 75 training epochs. The above change is
made for the purposes of more time-efficient calculation.
The accuracy of prediction is very similar to that of the
standard set.
xgboost: Extreme Gradient Boosting method published
in ref41. In this paper, we are using a set of standard
parameters from Merck’s subsequent study using this
method42.
IV. TABLES
V. FIGURES
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FIG. 7: Multitask framework for PotentialNet training
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TABLE I: Aggregate performance: Temporal Split
Metric Value
Mean RandomForest Rˆ2 0.30
Mean PotentialNet Rˆ2 0.44
Median RandomForest Rˆ2 0.27
Median PotentialNet Rˆ2 0.43
Mean Absolute Rˆ2 Improvement 0.15
Mean Percentage Rˆ2 Improvement 64%
Median Absolute Rˆ2 Improvement 0.16
Median Percentage Rˆ2 Improvement 52%
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TABLE II: Aggregate Statistics: Temporal plus Molecular Weight Split
Metric Value
Mean RandomForest Rˆ2 0.12
Mean PotentialNet Rˆ2 0.28
Median RandomForest Rˆ2 0.12
Median PotentialNet Rˆ2 0.25
Mean Absolute Rˆ2 Improvement 0.16
Mean Percentage Rˆ2 Improvement 1477%
Median Absolute Rˆ2 Improvement 0.16
Median Percentage Rˆ2 Improvement 153%
TABLE III: Aggregate performance: Prospective
Metric Value
Mean RandomForest Rˆ2 0.34
Mean PotentialNet Rˆ2 0.45
Median RandomForest Rˆ2 0.32
Median PotentialNet Rˆ2 0.43
Mean Absolute Rˆ2 Improvement 0.10
Mean Percentage Rˆ2 Improvement 37%
Median Absolute Rˆ2 Improvement 0.10
Median Percentage Rˆ2 Improvement 35%
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TABLE IV: Temporal Split: Commercially Available Molecules for which performance improvement of PotentialNet
with graph features over Random Forest with pair features is greatest
Molecule Property Exp. RandomForest PotentialNet SMILES
logD 3.88 2.26 3.70 COC(=O)c1ccc(cc1I)Cl
logD -0.61 1.58 0.59 COc1ccc(c(c1F)C(=O)N)F
Human Fraction Unbound -0.06 -1.30 -0.45
Cc1c(nc[nH]1)
CSCCN/C(=N/C#N)/NC
Human Fraction Unbound -2.95 -2.24 -3.07
C[C@@H]([C@@H](Cc1ccc(cc1)Cl)
c2cccc(c2)C#N)NC(=O)C(C)
(C)Oc3ccc(cn3)C(F)(F)F
CYP3A4 Inhibition 6.14 4.61 5.54
Cc1cc(n[nH]1)CN(C)c2ncc
(c(n2)C3CC3)c4ccncc4
hERG Inhibition 6.62 5.17 5.80
CCOC(=O)CCNc1cc(nc(n1)
c2ccccn2)N3CCc4ccccc4CC3
TABLE V: Temporal Split: Example of molecule predicted more accurately by Random Forests than by PotentialNet
Molecule Property Exp. RandomForest PotentialNet SMILES
Human Fraction Unbound -1.51 -1.55 1.86
Cc1cc(no1)NC(=O)
Nc2cc(c(cc2OC)OC)Cl
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TABLE VI: Performance: Temporal Split
Dataset
RandomForest
Rˆ2
RandomForest
Rˆ2, 95% CI
PotentialNet
Rˆ2
PotentialNet
Rˆ2, 95% CI
Absolute
Improvement
Percentage
Improvement
HPLC EPSA 0.775 (0.76, 0.789) 0.772 (0.757, 0.786) -0.003 -0.340
Cl, rat 0.260 (0.25, 0.271) 0.272 (0.262, 0.282) 0.011 4.360
Cl, dog 0.277 (0.258, 0.295) 0.314 (0.296, 0.333) 0.038 13.579
t1/2, dog 0.209 (0.192, 0.225) 0.247 (0.23, 0.264) 0.038 18.455
MRT, rat (h) 0.084 (0.075, 0.093) 0.127 (0.117, 0.138) 0.044 52.333
Vdss, rat (L/kg) 0.345 (0.335, 0.356) 0.393 (0.383, 0.403) 0.048 13.769
t1/2, rat 0.168 (0.16, 0.177) 0.248 (0.239, 0.258) 0.080 47.625
PXR activation 0.348 (0.342, 0.353) 0.438 (0.432, 0.443) 0.090 25.933
solubility in FASSIF 0.203 (0.197, 0.208) 0.296 (0.291, 0.302) 0.094 46.178
PGP efflux, human 0.366 (0.35, 0.382) 0.489 (0.474, 0.503) 0.123 33.572
MRT, dog (h) 0.129 (0.112, 0.147) 0.253 (0.231, 0.274) 0.124 96.050
CYP2C8 IC50 0.343 (0.331, 0.355) 0.474 (0.462, 0.485) 0.130 38.029
PAMPA 0.604 (0.553, 0.651) 0.735 (0.697, 0.77) 0.131 21.752
CYP2C9 IC50 0.205 (0.2, 0.21) 0.346 (0.341, 0.352) 0.141 68.728
PGP efflux, rat 0.358 (0.341, 0.374) 0.502 (0.487, 0.517) 0.145 40.497
NaV 1.5 IC50 0.170 (0.164, 0.177) 0.328 (0.321, 0.336) 0.158 92.688
hERG inh (MK499) 0.291 (0.286, 0.295) 0.451 (0.447, 0.456) 0.161 55.306
hepatocyte Cl, dog 0.298 (0.266, 0.329) 0.459 (0.429, 0.489) 0.162 54.326
solubility at pH7 0.331 (0.327, 0.335) 0.496 (0.493, 0.5) 0.165 49.843
hepatocyte Cl, human 0.265 (0.252, 0.279) 0.431 (0.417, 0.444) 0.165 62.323
CYP2D6 IC50 0.135 (0.131, 0.14) 0.306 (0.3, 0.312) 0.171 126.063
hepatocyte Cl, rat 0.237 (0.223, 0.251) 0.408 (0.394, 0.422) 0.171 71.951
CaV 1.2 IC50 0.141 (0.135, 0.147) 0.316 (0.31, 0.323) 0.175 124.278
Papp, LLC-PK 0.520 (0.509, 0.532) 0.696 (0.688, 0.704) 0.176 33.781
HPLC logD 0.678 (0.67, 0.686) 0.861 (0.857, 0.865) 0.183 26.984
microsome Cl, human 0.382 (0.369, 0.394) 0.588 (0.578, 0.598) 0.206 53.992
microsome Cl, rat 0.320 (0.307, 0.333) 0.539 (0.528, 0.551) 0.219 68.500
CYP3A4 IC50 0.200 (0.194, 0.205) 0.420 (0.415, 0.426) 0.221 110.634
microsome Cl, dog 0.105 (0.076, 0.137) 0.361 (0.32, 0.402) 0.257 245.523
Fu,p human 0.251 (0.233, 0.27) 0.596 (0.58, 0.611) 0.344 136.910
Fu,p rat 0.233 (0.221, 0.245) 0.608 (0.598, 0.618) 0.375 161.049
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TABLE VII: Performance: Temporal plus Molecular Weight Split
Dataset
RandomForest
Rˆ2
RandomForest
Rˆ2, 95% CI
PotentialNet
Rˆ2
PotentialNet
Rˆ2, 95% CI
Absolute
Improvement
Percentage
Improvement
hepatocyte Cl, rat 0.142 (0.087, 0.206) 0.030 (0.007, 0.068) -0.112 -78.891
solubility in FASSIF 0.176 (0.158, 0.194) 0.136 (0.12, 0.153) -0.040 -22.804
Cl, rat 0.041 (0.025, 0.061) 0.039 (0.023, 0.059) -0.002 -5.284
Cl, dog 0.008 (0.0, 0.037) 0.008 (0.0, 0.037) -0.000 -0.281
MRT, rat (h) 0.049 (0.028, 0.074) 0.054 (0.032, 0.08) 0.005 10.590
hepatocyte Cl, human 0.017 (0.003, 0.044) 0.029 (0.008, 0.062) 0.012 67.114
CYP2D6 IC50 0.154 (0.134, 0.175) 0.188 (0.166, 0.21) 0.034 21.943
Vdss, rat (L/kg) 0.122 (0.095, 0.153) 0.182 (0.15, 0.216) 0.060 48.745
PGP efflux, human 0.043 (0.008, 0.101) 0.133 (0.066, 0.215) 0.091 212.901
t1/2, rat 0.000 (0.001, 0.004) 0.106 (0.081, 0.134) 0.106 23708.598
t1/2, dog 0.247 (0.176, 0.321) 0.377 (0.302, 0.451) 0.131 52.942
CYP3A4 IC50 0.111 (0.093, 0.129) 0.242 (0.219, 0.265) 0.131 118.507
CYP2C9 IC50 0.075 (0.061, 0.092) 0.214 (0.192, 0.236) 0.138 182.877
hERG inh (MK499) 0.135 (0.123, 0.148) 0.273 (0.258, 0.289) 0.138 102.122
CaV 1.2 IC50 0.021 (0.013, 0.031) 0.181 (0.159, 0.204) 0.160 767.023
PXR activation 0.201 (0.18, 0.223) 0.364 (0.341, 0.387) 0.163 80.830
PGP efflux, rat 0.063 (0.018, 0.132) 0.226 (0.14, 0.32) 0.163 256.734
microsome Cl, dog 0.371 (0.193, 0.544) 0.556 (0.385, 0.695) 0.185 49.751
NaV 1.5 IC50 0.018 (0.01, 0.028) 0.247 (0.222, 0.273) 0.229 1279.873
MRT, dog (h) 0.016 (0.0, 0.062) 0.249 (0.159, 0.346) 0.233 1416.502
CYP2C8 IC50 0.163 (0.116, 0.213) 0.412 (0.357, 0.466) 0.250 153.437
HPLC logD 0.397 (0.354, 0.439) 0.651 (0.618, 0.682) 0.254 63.935
solubility at pH7 0.124 (0.11, 0.138) 0.384 (0.367, 0.402) 0.261 210.535
Papp, LLC-PK 0.137 (0.088, 0.194) 0.418 (0.354, 0.479) 0.280 204.100
microsome Cl, human 0.139 (0.089, 0.196) 0.430 (0.366, 0.491) 0.291 208.433
microsome Cl, rat 0.146 (0.094, 0.205) 0.519 (0.457, 0.577) 0.373 255.865
hepatocyte Cl, dog 0.003 (0.012, 0.047) 0.387 (0.259, 0.509) 0.384 12724.229
Fu,p human 0.154 (0.11, 0.202) 0.542 (0.493, 0.587) 0.387 251.270
Fu,p rat 0.097 (0.065, 0.134) 0.567 (0.526, 0.606) 0.470 486.274
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TABLE VIII: Performance: Prospective Split
Dataset
RandomForest
Rˆ2
RandomForest
Rˆ2, 95% CI
PotentialNet
Rˆ2
PotentialNet
Rˆ2, 95% CI
Absolute
Improvement
Percentage
Improvement
Cl, dog 0.231 (0.163, 0.304) 0.173 (0.111, 0.242) -0.058 -25.162
HPLC EPSA 0.819 (0.806, 0.831) 0.781 (0.765, 0.795) -0.039 -4.710
Cl, rat 0.350 (0.317, 0.384) 0.330 (0.297, 0.363) -0.020 -5.770
t1/2, dog 0.326 (0.257, 0.396) 0.326 (0.257, 0.395) -0.001 -0.162
t1/2, rat 0.318 (0.285, 0.351) 0.319 (0.286, 0.352) 0.001 0.215
Vdss, rat (L/kg) 0.520 (0.49, 0.55) 0.525 (0.494, 0.554) 0.004 0.846
microsome Cl, human 0.542 (0.503, 0.579) 0.579 (0.542, 0.614) 0.037 6.878
microsome Cl, rat 0.478 (0.436, 0.519) 0.541 (0.501, 0.579) 0.063 13.069
CYP2C9 IC50 0.257 (0.232, 0.282) 0.322 (0.296, 0.347) 0.065 25.396
CaV 1.2 IC50 0.120 (0.103, 0.138) 0.192 (0.172, 0.213) 0.072 59.540
NaV 1.5 IC50 0.137 (0.119, 0.155) 0.213 (0.192, 0.234) 0.076 55.582
solubility in FASSIF 0.199 (0.188, 0.21) 0.286 (0.274, 0.298) 0.087 43.823
CYP3A4 IC50 0.255 (0.236, 0.274) 0.344 (0.325, 0.364) 0.089 35.108
PAMPA 0.378 (0.305, 0.45) 0.474 (0.403, 0.541) 0.096 25.487
PXR activation 0.325 (0.308, 0.342) 0.431 (0.414, 0.448) 0.106 32.608
PGP efflux, human 0.349 (0.252, 0.446) 0.468 (0.372, 0.557) 0.119 33.934
CYP2D6 IC50 0.287 (0.261, 0.313) 0.406 (0.38, 0.432) 0.120 41.735
Papp, LLC-PK 0.111 (0.066, 0.164) 0.241 (0.18, 0.304) 0.129 116.526
hERG inh (MK499) 0.306 (0.286, 0.325) 0.445 (0.425, 0.464) 0.139 45.555
hepatocyte Cl, rat 0.195 (0.161, 0.231) 0.342 (0.305, 0.38) 0.147 75.254
Fu,p rat 0.481 (0.45, 0.511) 0.642 (0.617, 0.666) 0.161 33.522
hepatocyte Cl, dog 0.224 (0.15, 0.304) 0.407 (0.326, 0.486) 0.183 81.705
PGP efflux, rat 0.293 (0.076, 0.532) 0.477 (0.234, 0.681) 0.185 63.129
hepatocyte Cl, human 0.255 (0.22, 0.29) 0.445 (0.411, 0.479) 0.190 74.741
microsome Cl, dog 0.518 (0.136, 0.794) 0.739 (0.42, 0.899) 0.221 42.766
HPLC logD 0.402 (0.39, 0.413) 0.705 (0.697, 0.712) 0.303 75.503
Fu,p human 0.582 (0.3, 0.78) 0.919 (0.832, 0.962) 0.337 57.903
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TABLE IX: Temporal plus Molecular Weight Split: Commercially Available Molecules for which performance
improvement of PotentialNet with graph features over Random Forest with pair features is greatest
Molecule Property Exp. RandomForest PotentialNet SMILES
Rat Fraction Unbound -0.85 -2.17 -1.09
c1cc(cc(c1)F)c2cn
(nn2)[C@H]3[C@H]
([C@H](O[C@H]
([C@@H]3O)S[C@H]
4[C@@H]([C@H]
([C@H]([C@H](O4)CO)O)n5cc
(nn5)c6cccc(c6)F)O)CO)O
Human Fraction Unbound -1.17 -2.15 -1.60
C[C@H](Cn1cnc2c1ncnc2N)
OCP(=O)(N[C@@H]
(C)C(=O)OCc3ccccc3)
N[C@@H](C)C(=O)OCc4ccccc4
logD 4.55 3.02 4.43
Cc1cc(cc(c1)
Nc2nccc(n2)
c3cn(nn3)Cc4ccc
(cc4)OC)c5cnc(s5)C6
(CCC(CC6)C(=O)OC(C)(C)C)O
CYP2D6 Inhibition 4.30 4.95 4.53
C[C@H](Cn1cnc2c1ncnc2N)
OCP(=O)(N[C@@H](C)C
(=O)OCc3ccccc3)N[C@@H]
(C)C(=O)OCc4ccccc4
TABLE X: Performance on Held Out Data from Literature21
Property RandomForest R2 PotentialNet R2
Papp 0.150 (0.081, 0.232) 0.381 (0.292, 0.468)
logD 0.394 (0.305, 0.480) 0.603 (0.528, 0.670)
TABLE XI: Literature21 Molecules for which performance improvement of PotentialNet with graph features over
Random Forest with pair features is greatest
Molecule Property Exp. RandomForest PotentialNet SMILES
Papp 2.33 74.75 4.90
CO[C@H]1CC[C@H]2CCOc3ccc
(cc3C(=O)N(C)CCCC(=O)N(C)C[C@@H]1O2)C#N
Papp 74.34 21.51 52.42
C[C@@H(CO)N1C[C@@H(C[C@@H(CN(C)Cc2ccccc2)
OCCCC[C@@H(C)Oc3ccc(cc3C1=O)N(C)C
logD -0.70 1.93 0.34
C[C@H](CO)N1C[C@H](C)[C@H]
(CN(C)S(=O)(=O)C)OCc2cnnn2CCCC1=O
logD 4.70 2.63 3.74
COc1ccc(CN(C)C[C@H]2OCCCC[C@H]C)Oc3ccc(NS(=O)
(=O)c4ccc(Cl)cc4)cc3C(=O)N(C[C@H]2C)[C@@H](C)CO)cc1
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A. Performance of models trained on Merck data on held
out literature macrocycle data
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FIG. 8: Temporal Split: Scatter plots of predictions by PotentialNet and by Random Forest vs. Experiment for
Several Assays
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FIG. 9: Temporal plus Molecular Weight Split: Scatter plots of predictions by PotentialNet and by Random Forest vs.
Experiment for Several Assays
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FIG. 10: Nov, 2018 - Feb, 2019 Prospective Data: Scatter plots of predictions by PotentialNet and by Random Forest
vs. Experiment for Several Assays. All models were trained on data and compounds registered up through August,
2018 and tested prospectively on data and compounds registered in Nov, 2018 - Feb, 2019
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FIG. 11: Feature interpretation for macrocycle in ref21
22
FIG. 12: Scatter plots of predictions by models pre-trained on Merck data with both PotentialNet and Random Forest
vs. Experiment for logD Measurements on Macrocycles in ref21
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1Supplemental Figures
2TABLE I: Temporal plus Molecular Weight Split: Aggregate Performance Across all Datasets while only retaining
molecules with MW > 700 gmol in the test set
0
Mean RandomForest Rˆ2 0.091
Mean PotentialNet Rˆ2 0.189
Median RandomForest Rˆ2 0.063
Median PotentialNet Rˆ2 0.178
Mean Absolute Rˆ2 Improvement 0.098
Mean Percentage Rˆ2 Improvement 318.335
Median Absolute Rˆ2 Improvement 0.089
Median Percentage Rˆ2 Improvement 131.795
FIG. S1: Temporal plus Molecular Weight split: Scatter plot of errors for two models: ABS(PotentialNet -
Experiment) vs. ABS(Random Forest - Experiment) for Fu,p human
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3FIG. S2: Plot of R2 versus test set size for all datasets for temporal split. Train and test set sizes for each assay for
temporal split can be found in SI Figure VII. Test set size is a qualitatively weak predictor of performance for a deep
learning model.
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4FIG. S3: Temporal plus Molecular Weight split for different molecular weight cutoffs. For example, 550 on the
abscissa refers to cross-validation split where only molecules with molecular weight > 550 gmol are retained in the test
set. For each cross-validation split listed on the abscissa, only molecules with molecular weight < 500 gmol are retained
in the training and validation sets. Therefore, as one moves right along the abscissa, the train-test split becomes more
difficult for the machine learner since the gap in molecular weight between train and test molecules becomes larger,
forcing the model to do more extrapolation. While performance of both PotentialNet and Random Forests steadily
degrades the larger the gap in MW between train and test molecules, PotentialNet also retains an advantage for each
Temporal plus Molecular Weight split examined. Median R2 figures are reported over all assays for which there were
at least 100 molecules in the test set for a MW cutoff of 700 gmol .
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5FIG. S4: At its core, supervised ML revolves around finding patterns in past data to make predictions on future data.
An immediate corollary to this notion is the question of how much past data is needed to make accurate predictions
on future data? Here, we performed a training data ablation study. For each of the assay datasets, we temporally
removed different proportions of the training and validation data while leaving test data unchanged. For instance, at
60% data retained on the abscissa, we removed 40% of the training and validation data points that were temporally or
chronologically latest. Therefore, this is equivalent to introducing a time gap between the last training and validation
data point and the earliest test data point. Clearly, temporally removing training and validation data systematically
diminishes performance of both random forests and of PotentialNet. Nevertheless, the advantage of PotentialNet
versus Random Forests in terms of predictive performance remains qualitatively similar regardless of quantity of data
removed. It is intriguing that the signal increase from 80% to 100% is greater than that of 60% to 80%; perhaps this
reflects how the most similar ligands to those in the test set are most likely to be temporally adjacent as well.
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6TABLE II: Results on Temporal plus Molecular Weight Split with Random Forests (MIX and Scikit Learn), xgboost,
single task multilayer perceptron DNN, single task PotentialNet DNN, and multitask PotentialNet DNN. All results
reported with Pearson R2
RF: MIX RF: sklearn xgboost MLP DNN
PotentialNet
SingleTask
PotentialNet
MultiTask
Rat fraction unbound plasma-current 0.012 0.097 0.054 0.483 0.583 0.567
Ca Na Ion Channel NaV 1.5 Inhibition 0.012 0.018 0.000 0.235 0.235 0.247
LOGD 0.405 0.397 0.494 0.593 0.749 0.651
CLint Human hepatocyte 0.001 0.017 0.000 0.149 0.102 0.029
CYP Inhibition 3A4 0.084 0.111 0.087 0.158 0.228 0.242
PXR activation 0.089 0.201 0.037 0.354 0.343 0.364
CYP Inhibition 2D6 0.024 0.154 0.093 0.154 0.136 0.188
3A4 0.370 0.419 0.262 0.447 0.503 0.588
CLint Human microsome 0.202 0.139 0.258 0.174 0.274 0.430
CLint Rat hepatocyte 0.035 0.150 0.047 0.070 0.236 0.033
Human fraction unbound plasma-current 0.139 0.154 0.146 0.248 0.418 0.542
MK499 0.053 0.073 0.041 0.093 0.170 0.234
Volume of Distribution Rat 0.130 0.121 0.006 0.059 0.249 0.181
Halflife Rat 0.016 0.000 0.091 0.035 0.030 0.104
Halflife Dog 0.016 0.248 0.268 0.195 0.428 0.377
CLint Dog hepatocyte 0.087 0.003 0.048 0.064 0.491 0.387
dog MRT 0.042 0.020 0.000 0.003 0.047 0.255
CLint Dog microsome 0.036 0.371 0.346 0.388 0.493 0.556
Absorption Papp 0.181 0.137 0.064 0.119 0.333 0.418
Clearance Dog 0.006 0.008 0.001 0.010 0.084 0.008
Ca Na Ion Channel CaV 1.2 Inhibition 0.017 0.021 0.001 0.114 0.191 0.181
CYP Inhibition 2C8 0.063 0.163 0.031 0.238 0.358 0.412
Clearance Rat 0.065 0.041 0.015 0.275 0.014 0.039
CLint Rat microsome 0.201 0.146 0.259 0.155 0.362 0.519
CYP TDI 3A4 Ratio 0.001 0.000 0.026 0.108 0.121 0.099
TABLE III: Median ∆R2 over Random Forests for different ML model types on temporal plus MW split.
0
(RF: sklearn) - (RF: MIX) 0.006
(xgboost) - (RF: MIX) -0.001
(MLP DNN) - (RF: MIX) 0.097
(PotentialNet, SingleTask) - (RF: MIX) 0.152
(PotentialNet, MultiTask) - (RF: MIX) 0.218
7TABLE IV: Number of molecules in train and test sets for Temporal plus Molecular Weight split
n train mols n test mols
3A4 24904 855
Absorption Papp 22043 387
CLint Dog hepatocyte 2419 100
CLint Dog microsome 1381 50
CLint Human hepatocyte 15503 416
CLint Human microsome 22839 387
CLint Rat hepatocyte 14744 316
CLint Rat microsome 22065 364
CYP Inhibition 2C8 19149 524
CYP Inhibition 2C9 104095 2903
CYP Inhibition 2D6 103901 2845
CYP Inhibition 3A4 103189 2883
CYP TDI 3A4 Ratio 17387 352
Ca Na Ion Channel CaV 1.2 Inhibition 60305 2656
Ca Na Ion Channel NaV 1.5 Inhibition 56964 2308
Clearance Dog 10085 239
Clearance Rat 28563 1211
Halflife Dog 11125 282
Halflife Rat 31768 1332
Human fraction unbound plasma-current 10114 559
LOGD 27840 856
MK499 26466 892
PGP Human 1uM 16116 192
PGP Rat 1uM 14907 179
PXR activation 104203 3004
Rat MRT 17958 898
Rat fraction unbound plasma-current 20111 714
SOLY 7 221036 5129
Solubility Fassif 118524 4008
Volume of Distribution Rat 28821 1216
dog MRT 6830 173
hERG MK499 180285 6513
8TABLE V: Number of molecules in train and test sets for Prospective Study
n train mol n test mol
CYP2C9 IC50 206932 2483
CYP2D6 IC50 206565 2333
CYP3A4 IC50 204801 4121
CaV 1.2 IC50 135403 3304
Cl, dog 18875 295
Cl, rat 60190 1451
Fu,p human 17852 21
Fu,p rat 38583 1494
HPLC EPSA 8169 1844
HPLC logD 48914 11280
NaV 1.5 IC50 128359 3356
PAMPA 1700 300
PGP efflux, human 26104 169
PGP efflux, rat 23402 29
PXR activation 208309 5350
Papp, LLC-PK 40131 390
Vdss, rat (L/kg) 60307 1451
hERG inh (MK499) 340680 4011
hepatocyte Cl, dog 6474 243
hepatocyte Cl, human 33251 1249
hepatocyte Cl, rat 30511 1133
microsome Cl, dog 3826 13
microsome Cl, human 41922 849
microsome Cl, rat 39351 824
solubility in FASSIF 212259 10690
t1/2, dog 20720 332
t1/2, rat 66766 1490
9TABLE VI: Results on Temporal Split with Random Forests (sklearn implementation), single task PotentialNet DNN,
and multitask PotentialNet DNN. All results reported with Pearson R2
Random Forest Rˆ2 PotentialNet, SingleTask PotentialNet, MultiTask
3A4 0.450 0.630 0.658
Absorption Papp 0.520 0.641 0.696
CLint Dog hepatocyte 0.298 0.378 0.459
CLint Dog microsome 0.105 0.119 0.361
CLint Human hepatocyte 0.265 0.390 0.431
CLint Human microsome 0.382 0.553 0.588
CLint Rat hepatocyte 0.237 0.354 0.408
CLint Rat microsome 0.320 0.500 0.539
CYP Inhibition 2C8 0.343 0.391 0.474
CYP Inhibition 2C9 0.205 0.342 0.346
CYP Inhibition 2D6 0.135 0.291 0.306
CYP Inhibition 3A4 0.200 0.404 0.420
CYP TDI 3A4 Ratio 0.032 0.025 0.032
Ca Na Ion Channel CaV 1.2 Inhibition 0.141 0.277 0.316
Ca Na Ion Channel NaV 1.5 Inhibition 0.170 0.288 0.328
Clearance Dog 0.277 0.289 0.314
Clearance Rat 0.260 0.275 0.272
EPSA 0.775 0.758 0.772
Halflife Dog 0.209 0.201 0.247
Halflife Rat 0.168 0.218 0.248
Human fraction unbound plasma-current 0.251 0.445 0.596
LOGD 0.678 0.850 0.861
MK499 0.288 0.375 0.433
PAMPA 0.604 0.729 0.735
PGP Human 1uM 0.366 0.405 0.489
PGP Rat 1uM 0.358 0.356 0.502
PXR activation 0.348 0.446 0.438
Rat MRT 0.084 0.129 0.127
Rat fraction unbound plasma-current 0.233 0.542 0.608
SOLY 7 0.331 0.491 0.496
Solubility Fassif 0.203 0.267 0.296
Volume of Distribution Rat 0.345 0.382 0.393
dog MRT 0.129 0.191 0.253
hERG MK499 0.291 0.436 0.451
TABLE VII: Median ∆R2 over Random Forests for different ML model types on temporal split.
0
(PotentialNet, SingleTask) - (Random Forest Rˆ2) 0.108
(PotentialNet, MultiTask) - (Random Forest Rˆ2) 0.152
10
TABLE VIII: Number of molecules in train and test sets for temporal split
n train mols n test mols
3A4 36004 12001
Absorption Papp 30097 10032
CLint Dog hepatocyte 4854 1618
CLint Dog microsome 2868 956
CLint Human hepatocyte 24937 8312
CLint Human microsome 31440 10480
CLint Rat hepatocyte 22882 7627
CLint Rat microsome 29512 9837
CYP Inhibition 2C8 34601 11533
CYP Inhibition 2C9 155198 51732
CYP Inhibition 2D6 154922 51641
CYP Inhibition 3A4 153599 51200
CYP TDI 3A4 Ratio 27040 9013
Ca Na Ion Channel CaV 1.2 Inhibition 101551 33850
Ca Na Ion Channel NaV 1.5 Inhibition 96268 32089
Clearance Dog 14155 4718
Clearance Rat 45141 15047
EPSA 6125 2042
Halflife Dog 15539 5179
Halflife Rat 50073 16691
Human fraction unbound plasma-current 13388 4462
LOGD 36684 12228
MK499 36677 12226
PAMPA 1274 424
PGP Human 1uM 19577 6525
PGP Rat 1uM 17550 5850
PXR activation 156230 52077
Rat MRT 29108 9703
Rat fraction unbound plasma-current 28936 9645
SOLY 7 290960 96986
Solubility Fassif 159193 53064
Volume of Distribution Rat 45229 15076
dog MRT 10035 3345
hERG MK499 255509 85169
11
TABLE IX: Results on select Merck KAGGLE datasets
Dataset
RandomForest
Rˆ2
RandomForest
Rˆ2, 95% CI
PotentialNet
Rˆ2
PotentialNet
Rˆ2, 95% CI
Absolute
Improvement
Percentage
Improvement
2C8 0.178 (0.165, 0.191) 0.296 (0.281, 0.31) 0.118 66.128
2C9BIG 0.304 (0.298, 0.31) 0.424 (0.419, 0.43) 0.120 39.421
2D6 0.148 (0.139, 0.158) 0.265 (0.253, 0.276) 0.116 78.123
3A4small 0.434 (0.423, 0.445) 0.629 (0.62, 0.637) 0.195 44.894
ANRINA 0.014 (0.003, 0.033) 0.047 (0.024, 0.077) 0.033 228.103
BACE 0.636 (0.622, 0.651) 0.638 (0.624, 0.652) 0.002 0.304
CAV 0.400 (0.389, 0.411) 0.503 (0.493, 0.513) 0.103 25.761
CB1 0.331 (0.307, 0.354) 0.347 (0.323, 0.37) 0.016 4.928
CLINT 0.401 (0.385, 0.418) 0.578 (0.564, 0.591) 0.176 43.919
DPP4expanded 0.227 (0.201, 0.254) 0.065 (0.048, 0.083) -0.163 -71.529
ERK2 0.251 (0.23, 0.273) 0.291 (0.269, 0.313) 0.039 15.611
FACTORXIA 0.238 (0.213, 0.263) 0.249 (0.224, 0.274) 0.011 4.654
FASSIF 0.295 (0.287, 0.304) 0.363 (0.354, 0.371) 0.068 22.950
HERGBIG 0.297 (0.293, 0.301) 0.442 (0.437, 0.446) 0.145 48.684
HIV INTEGRASE cell 0.386 (0.335, 0.437) 0.416 (0.365, 0.466) 0.030 7.638
HIV PROTEASE 0.162 (0.13, 0.197) 0.076 (0.053, 0.104) -0.086 -52.968
METAB 0.545 (0.495, 0.592) 0.541 (0.491, 0.588) -0.004 -0.742
NAV 0.290 (0.278, 0.302) 0.440 (0.429, 0.452) 0.150 51.763
NK1 0.025 (0.017, 0.035) 0.096 (0.081, 0.113) 0.071 277.424
OX1 0.502 (0.474, 0.53) 0.370 (0.34, 0.4) -0.133 -26.409
OX2 0.577 (0.559, 0.594) 0.526 (0.508, 0.545) -0.050 -8.727
PPB 0.410 (0.387, 0.433) 0.618 (0.599, 0.636) 0.208 50.751
PXRsmall 0.343 (0.331, 0.354) 0.415 (0.404, 0.426) 0.072 21.115
Papp 0.608 (0.596, 0.619) 0.712 (0.702, 0.721) 0.104 17.069
TDI ratio 0.380 (0.346, 0.413) 0.401 (0.367, 0.435) 0.022 5.690
THROMBIN 0.265 (0.235, 0.295) 0.268 (0.238, 0.298) 0.003 1.077
mk499small 0.298 (0.287, 0.31) 0.492 (0.481, 0.502) 0.193 64.795
partcosmall 0.677 (0.669, 0.685) 0.847 (0.843, 0.851) 0.170 25.069
pgp 0.550 (0.525, 0.573) 0.628 (0.606, 0.649) 0.078 14.199
rat F 0.118 (0.095, 0.143) 0.165 (0.138, 0.192) 0.047 39.442
TABLE X: Aggregate Results on select Merck KAGGLE datasets
0
Mean RandomForest Rˆ2 0.343
Mean PotentialNet Rˆ2 0.405
Median RandomForest Rˆ2 0.318
Median PotentialNet Rˆ2 0.416
Mean Absolute Rˆ2 Improvement 0.062
Mean Percentage Rˆ2 Improvement 34.638
Median Absolute Rˆ2 Improvement 0.069
Median Percentage Rˆ2 Improvement 22.033
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TABLE XI: Temporal split: Spearman Rho for Random Forest and PotentialNet predictions
Dataset
RandomForest
Rho
RandomForest
Rho, 95% CI
PotentialNet
Rho
PotentialNet
Rho, 95% CI
Absolute
Improvement
Percentage
Improvement
t1/2, dog 0.445 (0.423, 0.467) 0.447 (0.425, 0.468) 0.002 0.341
HPLC EPSA 0.889 (0.879, 0.898) 0.891 (0.882, 0.9) 0.002 0.248
Cl, dog 0.526 (0.505, 0.547) 0.544 (0.524, 0.564) 0.018 3.462
Cl, rat 0.478 (0.466, 0.491) 0.510 (0.498, 0.521) 0.031 6.524
Vdss, rat (L/kg) 0.583 (0.573, 0.594) 0.620 (0.61, 0.63) 0.037 6.264
PAMPA 0.757 (0.713, 0.795) 0.820 (0.786, 0.849) 0.063 8.279
MRT, rat (h) 0.284 (0.266, 0.303) 0.353 (0.335, 0.37) 0.068 23.936
PXR activation 0.645 (0.64, 0.65) 0.713 (0.709, 0.717) 0.068 10.573
CYP2D6 IC50 0.367 (0.359, 0.374) 0.435 (0.428, 0.442) 0.069 18.751
PGP efflux, human 0.639 (0.625, 0.653) 0.721 (0.709, 0.732) 0.082 12.784
Papp, LLC-PK 0.566 (0.553, 0.579) 0.668 (0.657, 0.679) 0.102 17.961
t1/2, rat 0.392 (0.379, 0.405) 0.495 (0.483, 0.506) 0.102 26.062
PGP efflux, rat 0.585 (0.568, 0.602) 0.692 (0.679, 0.705) 0.107 18.281
HPLC logD 0.829 (0.824, 0.835) 0.937 (0.934, 0.939) 0.107 12.916
solubility in FASSIF 0.423 (0.415, 0.429) 0.537 (0.531, 0.543) 0.114 27.067
CYP3A4 IC50 0.404 (0.397, 0.411) 0.522 (0.516, 0.528) 0.118 29.179
hERG inh (MK499) 0.528 (0.524, 0.533) 0.659 (0.656, 0.663) 0.131 24.779
CYP2C8 IC50 0.562 (0.549, 0.574) 0.696 (0.686, 0.705) 0.134 23.855
hepatocyte Cl, rat 0.479 (0.461, 0.496) 0.622 (0.608, 0.636) 0.144 29.988
microsome Cl, human 0.607 (0.594, 0.619) 0.751 (0.742, 0.759) 0.144 23.740
hepatocyte Cl, human 0.517 (0.501, 0.533) 0.665 (0.653, 0.677) 0.148 28.566
CYP2C9 IC50 0.460 (0.453, 0.466) 0.610 (0.604, 0.615) 0.150 32.617
NaV 1.5 IC50 0.353 (0.344, 0.363) 0.505 (0.496, 0.513) 0.151 42.867
solubility at pH7 0.579 (0.575, 0.583) 0.731 (0.728, 0.734) 0.152 26.237
MRT, dog (h) 0.291 (0.26, 0.322) 0.453 (0.426, 0.48) 0.162 55.610
microsome Cl, rat 0.567 (0.553, 0.58) 0.733 (0.723, 0.742) 0.166 29.211
CaV 1.2 IC50 0.350 (0.341, 0.359) 0.535 (0.527, 0.542) 0.185 52.768
hepatocyte Cl, dog 0.482 (0.443, 0.518) 0.667 (0.639, 0.693) 0.185 38.486
Fu,p human 0.479 (0.456, 0.501) 0.759 (0.746, 0.771) 0.280 58.452
Fu,p rat 0.444 (0.428, 0.46) 0.776 (0.768, 0.784) 0.331 74.540
microsome Cl, dog 0.288 (0.229, 0.345) 0.630 (0.59, 0.667) 0.342 118.522
TABLE XII: Temporal split: spearman’s rho, aggregate results
Metric Value
Mean RandomForest Rho 0.5096
Mean PotentialNet Rho 0.6354
Median RandomForest Rho 0.4820
Median PotentialNet Rho 0.6590
Mean Absolute Rho Improvement 0.1256
Mean Percentage Rho Improvement 28.4795
Median Absolute Rho Improvement 0.1180
Median Percentage Rho Improvement 24.7790
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TABLE XIII: Temporal plus MW split: Spearman Rho for Random Forest and PotentialNet predictions
Dataset
RandomForest
Rho
RandomForest
Rho, 95% CI
PotentialNet
Rho
PotentialNet
Rho, 95% CI
Absolute
Improvement
Percentage
Improvement
hepatocyte Cl, rat 0.421 (0.326, 0.507) 0.065 (-0.046, 0.174) -0.356 -84.643
Cl, dog 0.210 (0.085, 0.328) 0.080 (-0.047, 0.204) -0.130 -62.032
Cl, rat 0.224 (0.17, 0.277) 0.133 (0.077, 0.188) -0.092 -40.800
hepatocyte Cl, human 0.204 (0.11, 0.294) 0.154 (0.058, 0.246) -0.050 -24.634
solubility in FASSIF 0.431 (0.406, 0.456) 0.388 (0.362, 0.414) -0.043 -9.935
CYP2D6 IC50 0.388 (0.357, 0.419) 0.400 (0.368, 0.43) 0.011 2.899
PGP efflux, human 0.313 (0.179, 0.435) 0.346 (0.215, 0.465) 0.033 10.638
MRT, rat (h) 0.207 (0.144, 0.269) 0.271 (0.209, 0.33) 0.063 30.624
PGP efflux, rat 0.398 (0.268, 0.515) 0.468 (0.346, 0.575) 0.070 17.579
CYP3A4 IC50 0.299 (0.265, 0.332) 0.387 (0.356, 0.418) 0.089 29.709
Vdss, rat (L/kg) 0.323 (0.272, 0.373) 0.417 (0.37, 0.463) 0.094 29.056
hERG inh (MK499) 0.332 (0.311, 0.354) 0.450 (0.43, 0.469) 0.117 35.231
PXR activation 0.507 (0.48, 0.533) 0.644 (0.622, 0.664) 0.137 26.992
microsome Cl, dog 0.542 (0.313, 0.711) 0.686 (0.506, 0.809) 0.144 26.591
t1/2, dog 0.436 (0.336, 0.526) 0.588 (0.506, 0.659) 0.152 34.790
CYP2C9 IC50 0.261 (0.227, 0.295) 0.457 (0.427, 0.485) 0.195 74.813
HPLC logD 0.580 (0.534, 0.623) 0.787 (0.76, 0.811) 0.207 35.668
CaV 1.2 IC50 0.128 (0.09, 0.165) 0.355 (0.321, 0.387) 0.227 178.001
CYP2C8 IC50 0.404 (0.33, 0.474) 0.640 (0.587, 0.688) 0.236 58.346
microsome Cl, rat 0.456 (0.37, 0.533) 0.705 (0.649, 0.753) 0.249 54.582
Papp, LLC-PK 0.269 (0.175, 0.359) 0.531 (0.456, 0.599) 0.262 97.154
microsome Cl, human 0.360 (0.27, 0.444) 0.642 (0.579, 0.697) 0.282 78.260
t1/2, rat 0.027 (-0.027, 0.081) 0.336 (0.287, 0.382) 0.309 1138.229
NaV 1.5 IC50 0.051 (0.01, 0.092) 0.362 (0.326, 0.397) 0.310 605.720
MRT, dog (h) 0.204 (0.057, 0.342) 0.522 (0.405, 0.622) 0.318 155.780
Fu,p human 0.417 (0.346, 0.483) 0.746 (0.707, 0.78) 0.328 78.727
solubility at pH7 0.309 (0.284, 0.333) 0.666 (0.651, 0.681) 0.358 115.897
Fu,p rat 0.350 (0.284, 0.412) 0.788 (0.759, 0.814) 0.438 125.390
hepatocyte Cl, dog 0.080 (-0.118, 0.271) 0.574 (0.426, 0.692) 0.494 620.724
TABLE XIV: Temporal plus MW split: spearman’s rho, aggregate results
Metric Value
Mean RandomForest Rho 0.3149
Mean PotentialNet Rho 0.4686
Median RandomForest Rho 0.3230
Median PotentialNet Rho 0.4570
Mean Absolute Rho Improvement 0.1535
Mean Percentage Rho Improvement 118.5985
Median Absolute Rho Improvement 0.1520
Median Percentage Rho Improvement 35.2310
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TABLE XV: Prospective Study: Spearman Rho for Random Forest and PotentialNet Predictions
Dataset
RandomForest
Rho
RandomForest
Rho, 95% CI
PotentialNet
Rho
PotentialNet
Rho, 95% CI
Absolute
Improvement
Percentage
Improvement
Cl, dog 0.485 (0.392, 0.568) 0.421 (0.322, 0.51) -0.064 -13.260
t1/2, dog 0.600 (0.526, 0.664) 0.559 (0.48, 0.629) -0.040 -6.746
PGP efflux, rat 0.656 (0.381, 0.824) 0.648 (0.369, 0.82) -0.008 -1.276
Vdss, rat (L/kg) 0.653 (0.623, 0.682) 0.654 (0.624, 0.683) 0.001 0.155
Cl, rat 0.573 (0.537, 0.606) 0.580 (0.544, 0.613) 0.007 1.196
t1/2, rat 0.545 (0.508, 0.58) 0.558 (0.522, 0.592) 0.013 2.452
HPLC EPSA 0.832 (0.817, 0.846) 0.862 (0.85, 0.874) 0.030 3.659
microsome Cl, human 0.732 (0.7, 0.762) 0.768 (0.739, 0.795) 0.036 4.900
CYP3A4 IC50 0.449 (0.424, 0.473) 0.517 (0.494, 0.539) 0.068 15.131
microsome Cl, rat 0.658 (0.617, 0.695) 0.726 (0.692, 0.757) 0.068 10.382
CYP2D6 IC50 0.489 (0.457, 0.519) 0.561 (0.533, 0.588) 0.073 14.845
NaV 1.5 IC50 0.346 (0.316, 0.376) 0.426 (0.398, 0.453) 0.080 22.971
PXR activation 0.604 (0.587, 0.621) 0.686 (0.672, 0.7) 0.082 13.562
CYP2C9 IC50 0.534 (0.505, 0.561) 0.626 (0.601, 0.649) 0.092 17.189
hepatocyte Cl, rat 0.480 (0.434, 0.524) 0.583 (0.543, 0.62) 0.103 21.372
PAMPA 0.544 (0.459, 0.619) 0.651 (0.58, 0.711) 0.107 19.656
Fu,p rat 0.686 (0.658, 0.712) 0.796 (0.777, 0.814) 0.111 16.153
PGP efflux, human 0.569 (0.457, 0.663) 0.689 (0.6, 0.761) 0.120 21.139
microsome Cl, dog 0.769 (0.378, 0.927) 0.891 (0.669, 0.967) 0.123 15.942
solubility in FASSIF 0.431 (0.416, 0.447) 0.555 (0.541, 0.568) 0.123 28.567
hERG inh (MK499) 0.524 (0.502, 0.546) 0.649 (0.631, 0.667) 0.125 23.838
hepatocyte Cl, human 0.552 (0.513, 0.59) 0.681 (0.65, 0.71) 0.128 23.257
Papp, LLC-PK 0.454 (0.371, 0.529) 0.583 (0.514, 0.645) 0.130 28.604
CaV 1.2 IC50 0.272 (0.24, 0.303) 0.405 (0.377, 0.434) 0.134 49.196
hepatocyte Cl, dog 0.324 (0.206, 0.432) 0.533 (0.436, 0.617) 0.209 64.654
HPLC logD 0.632 (0.621, 0.643) 0.846 (0.841, 0.852) 0.214 33.843
Fu,p human 0.574 (0.189, 0.806) 0.957 (0.896, 0.983) 0.383 66.818
TABLE XVI: Prospective study: spearman’s rho, aggregate results
Metric Value
Mean RandomForest Rho 0.5543
Mean PotentialNet Rho 0.6449
Median RandomForest Rho 0.5520
Median PotentialNet Rho 0.6480
Mean Absolute Rho Improvement 0.0907
Mean Percentage Rho Improvement 18.4518
Median Absolute Rho Improvement 0.0920
Median Percentage Rho Improvement 16.1530
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FIG. S5: To use a more traditional metric of molecular similarity to motivate an additional cross-validation procedure,
for each assay dataset, we selected newer test molecules with varying maximum Tanimoto similarities to the older
training molecules. The training set is identical to that used in temporal split, and the test sets are Tanimoto
cutoff-based subsets of the temporal test sets. We only included assays for which there were at least one hundred
molecules with a maximum Tanimto similarity less than 0.3 to the training set. Temporal plus Tanimoto split:
Aggregate R2 versus Tanimoto similarity cutoff for CYP2C9 Inhibition, CYP2D6 Inhibition, CYP3A4 Inhibition, CaV
1.2 Inhibition, NaV 1.5 Inhibition, PXR Activation, Solubility at pH7, Solubility in FASSIF, and hERG Inhibition.
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FIG. S6: Temporal plus Tanimoto split: Aggregate R2 versus Tanimoto similarity cutoff for hERG Inhibition.
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TABLE XVII: Assay names map
short name name w units
alt name
3A4 CYP3A4 IC50 CYP 3A4 IC50 (uM)
Absorption Papp Papp, LLC-PK
CLint Dog hepatocyte hepatocyte Cl, dog hepatocyte Cl, dog (ml/min/kg)
CLint Dog microsome microsome Cl, dog microsome Cl, dog (ml/min/kg)
CLint Human hepatocyte hepatocyte Cl, human hepatocyte Cl, human (ml/min/kg)
CLint Human microsome microsome Cl, human microsome Cl, human (ml/min/kg)
CLint Rat hepatocyte hepatocyte Cl, rat hepatocyte Cl, rat (ml/min/kg)
CLint Rat microsome microsome Cl, rat microsome Cl, rat (ml/min/kg)
CYP Inhibition 2C8 CYP2C8 IC50 CYP 2C8 IC50 (uM)
CYP Inhibition 2C9 CYP2C9 IC50 CYP 2C9 IC50 (uM)
CYP Inhibition 2D6 CYP2D6 IC50 CYP 2D6 IC50 (uM)
CYP Inhibition 3A4 CYP3A4 IC50 CYP 3A4 IC50 (uM)
CYP TDI 3A4 Ratio CYP3A4 TDI CYP 3A4 TDI IC50 (uM)
Ca Na Ion Channel CaV 1.2 Inhibition CaV 1.2 IC50 CaV 1.2 IC50 (uM)
Ca Na Ion Channel NaV 1.5 Inhibition NaV 1.5 IC50 NaV 1.5 IC50 (uM)
Clearance Dog Cl, dog Cl, dog (ml/min/kg)
Clearance Rat Cl, rat Cl, rat (ml/min/kg)
EPSA HPLC EPSA
Halife Dog t1/2, dog t1/2, dog (hr)
Halife Rat t1/2, rat t1/2, rat (hr)
Human fraction unbound plasma Fu,p human PPB, human (% unbound)
LOGD HPLC logD logD
MK499 hERG inh (MK499) hERG inh (MK499) (uM)
PGP Human 1uM PGP efflux, humany¨
PGP Rat 1uM PGP efflux, raty¨
PXR activation PXR activation PXR maximum activation relative to rifampicin
Rat MRT MRT, rat (h)
